Skip to main content
Top
Published in: Ophthalmology and Therapy 1/2017

Open Access 01-06-2017 | Original Research

Gas Tamponade for Retinectomy in PVR-Related Retinal Detachments: A Retrospective Study

Authors: Vasileios T. Papastavrou, Irini Chatziralli, Dominic McHugh

Published in: Ophthalmology and Therapy | Issue 1/2017

Login to get access

Abstract

Introduction

The purpose of the study was to evaluate the anatomical and functional results in patients with proliferative vitreoretinopathy (PVR) treated with retinectomy and perfluoro-octane gas (C3F8) as a tamponade agent.

Methods

12 patients with inferior and anterior complicated PVR-related retinal detachment, who were treated with retinectomy, where C3F8 was used as the tamponade agent were examined. Primary outcome was the anatomical success, while visual acuity, existence of an epiretinal membrane (ERM) and intraocular pressure (IOP) postoperatively were secondary outcomes.

Results

The primary success rate was 75% (mean follow-up of 9.8 months). Reoperation was needed on 25% of patients after the retinectomy procedure. Preoperative best corrected visual acuity (BCVA) was poor due to macular involvement in all cases. BCVA was improved in three patients (25%), remained stable in 25% and deteriorated in 16.7%. Two patients were lost during the follow-up period. Postoperative ERM formation was noted in 33.3% of patients. One patient developed hypotony, while no other complications were observed.

Conclusion

Retinectomy with C3F8 as the tamponade agent provides anatomical and functional restoration at a 75% primary success rate in PVR-related retinal detachment.
Literature
1.
go back to reference Khan MA, Brady CJ, Kaiser RS. Clinical management of proliferative vitreoretinopathy: an update. Retina. 2015;35:165–75.CrossRefPubMed Khan MA, Brady CJ, Kaiser RS. Clinical management of proliferative vitreoretinopathy: an update. Retina. 2015;35:165–75.CrossRefPubMed
2.
go back to reference Grigoropoulos VG, Benson S, Bunce C, Charteris DG. Functional outcome and prognostic factors in 304 eyes managed by retinectomy. Graefes Arch Clin Exp Ophthalmol. 2007;245:641–9.CrossRefPubMed Grigoropoulos VG, Benson S, Bunce C, Charteris DG. Functional outcome and prognostic factors in 304 eyes managed by retinectomy. Graefes Arch Clin Exp Ophthalmol. 2007;245:641–9.CrossRefPubMed
3.
go back to reference Machemer R, Aaberg TM, Freeman HM, Irvine AR, Lean JS, Michels RM. An updated classification of retinal detachment with proliferative vitreoretinopathy. Am J Ophthalmol. 1991;112:159–65.CrossRefPubMed Machemer R, Aaberg TM, Freeman HM, Irvine AR, Lean JS, Michels RM. An updated classification of retinal detachment with proliferative vitreoretinopathy. Am J Ophthalmol. 1991;112:159–65.CrossRefPubMed
4.
go back to reference Lee JW, Lai JS, Yick DW, Tse RK. Retrospective case series on the long-term visual and intraocular pressure outcomes of phacomorphic glaucoma. Eye. 2010;24:1675–80.CrossRefPubMed Lee JW, Lai JS, Yick DW, Tse RK. Retrospective case series on the long-term visual and intraocular pressure outcomes of phacomorphic glaucoma. Eye. 2010;24:1675–80.CrossRefPubMed
5.
go back to reference de Juan E, Jr McCuen B, Tiedeman J. Intraocular tamponade and surface tension. Surv Ophthalmol. 1985;30:47–51.CrossRefPubMed de Juan E, Jr McCuen B, Tiedeman J. Intraocular tamponade and surface tension. Surv Ophthalmol. 1985;30:47–51.CrossRefPubMed
6.
go back to reference Blumenkranz MS, Azen SP, Aaberg T, et al. Relaxing retinotomy with silicone oil or long-acting gas in eyes with severe proliferative vitreoretinopathy. Silicone Study Report 5. Am J Ophthalmol. 1993;116:557–64.CrossRefPubMed Blumenkranz MS, Azen SP, Aaberg T, et al. Relaxing retinotomy with silicone oil or long-acting gas in eyes with severe proliferative vitreoretinopathy. Silicone Study Report 5. Am J Ophthalmol. 1993;116:557–64.CrossRefPubMed
7.
go back to reference Quiram PA, Gonzales CR, Hu W, et al. Outcomes of vitrectomy with inferior retinectomy in patients with recurrent rhegmatogenous retinal detachments and proliferative vitreoretinopathy. Ophthalmology. 2006;113:2041–7.CrossRefPubMed Quiram PA, Gonzales CR, Hu W, et al. Outcomes of vitrectomy with inferior retinectomy in patients with recurrent rhegmatogenous retinal detachments and proliferative vitreoretinopathy. Ophthalmology. 2006;113:2041–7.CrossRefPubMed
8.
go back to reference Shalaby KA. Relaxing retinotomies and retinectomies in the management of retinal detachment with severe proliferative vitreoretinopathy (PVR). Clin Ophthalmol. 2010;4:1107–14.CrossRefPubMedPubMedCentral Shalaby KA. Relaxing retinotomies and retinectomies in the management of retinal detachment with severe proliferative vitreoretinopathy (PVR). Clin Ophthalmol. 2010;4:1107–14.CrossRefPubMedPubMedCentral
9.
go back to reference Sheng Y, Sun W, Mo B, Yu YJ, Gu YS, Liu W. Non-buckled vitrectomy for retinal detachment with inferior breaks and proliferative vitreoretinophathy. Int J Ophthalmol. 2012;5:591–5.PubMedPubMedCentral Sheng Y, Sun W, Mo B, Yu YJ, Gu YS, Liu W. Non-buckled vitrectomy for retinal detachment with inferior breaks and proliferative vitreoretinophathy. Int J Ophthalmol. 2012;5:591–5.PubMedPubMedCentral
10.
go back to reference Tan HS, Mura M, Oberstein SY, de Smet MD. Primary retinectomy in proliferative vitreoretinopathy. Am J Ophthalmol. 2010;149:447–52.CrossRefPubMed Tan HS, Mura M, Oberstein SY, de Smet MD. Primary retinectomy in proliferative vitreoretinopathy. Am J Ophthalmol. 2010;149:447–52.CrossRefPubMed
Metadata
Title
Gas Tamponade for Retinectomy in PVR-Related Retinal Detachments: A Retrospective Study
Authors
Vasileios T. Papastavrou
Irini Chatziralli
Dominic McHugh
Publication date
01-06-2017
Publisher
Springer Healthcare
Published in
Ophthalmology and Therapy / Issue 1/2017
Print ISSN: 2193-8245
Electronic ISSN: 2193-6528
DOI
https://doi.org/10.1007/s40123-017-0078-6

Other articles of this Issue 1/2017

Ophthalmology and Therapy 1/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine